FDA to remove "black box" warnings on some menopause hormone therapies

Key Concepts

• Hormone Therapy (HT): Medications containing estrogen and progesterone used to alleviate menopausal and perimenopausal symptoms.
• Black Box Warnings: The most serious type of warning issued by the FDA, indicating potential life-threatening risks associated with a drug.
• Women's Health Initiative (WHI) Study: The 2002 study that initially led to the FDA's black box warnings on hormone therapy.
• Bioidentical Hormones: Hormones that are chemically identical to those produced by the human body.
• Non-Bioidentical/Human Identical Hormones: Hormones that are not chemically identical to those produced by the human body.
• Menopause and Perimenopause: Transitional periods in a woman's life characterized by hormonal changes and associated symptoms.
• Cognitive Decline: A decrease in mental abilities such as memory, thinking, and reasoning.
• Cardiovascular Disease: Diseases affecting the heart and blood vessels.
• Osteoporosis: A condition characterized by weakened bones, increasing the risk of fractures.

FDA's Removal of Safety Warnings for Hormone Therapy

The Food and Drug Administration (FDA) has announced the removal of safety warnings for many hormone therapy (HT) drugs prescribed to manage symptoms of menopause and perimenopause. These medications, which include estrogen and progesterone in various forms like pills, creams, and other therapies, previously carried "black box" labels. These warnings cautioned about potential increased risks of breast cancer, dementia, heart attack, and strokes.

FDA Commissioner's Perspective on the Study

In an exclusive interview with CBS News, FDA Commissioner Dr. Marty Makary stated that the study which supported the initial warnings was flawed. He argued that the study lacked statistical significance and that no subsequent clinical trials have demonstrated an increase in breast cancer mortality. Dr. Makary highlighted the long-term health benefits of HT, suggesting potential reductions in cognitive decline, heart attacks, bone fractures, and even certain cancers and diabetes, benefits that are often overlooked.

Expert Opinion on Hormone Therapy's Benefits

Dr. Erica Schwartz, founder of Evolved Science Medical Group and author of "Don't Let Your Dr. Kill You," elaborated on the benefits of HT. She stated that HT can prevent Alzheimer's, cancer, and osteoporosis, and supports cardiovascular health, ultimately helping women stay healthier for longer. Dr. Schwartz described the situation as a "nightmare for women" and noted that the FDA's initial decision in 2002, based on a flawed study, has been corrected by current medical understanding.

Critique of the Original Study (WHI)

Dr. Schwartz explained that the original study, the Women's Health Initiative (WHI), which led to the black box warnings, was inaccurate. The study examined women who were more than ten years past menopause and had pre-existing conditions such as diabetes and a history of smoking. Furthermore, the WHI study was conducted on non-bioidentical or "human identical" hormones, which are fundamentally different from the bioidentical hormones necessary for women's health. Dr. Schwartz emphasized that this study was flawed from its inception and that it has been an "uphill battle" to rectify the FDA's decision, which has caused millions of women to suffer unnecessarily.

Impact on Patients and Future Outlook

Dr. Schwartz believes the FDA's decision will make a significant difference in the lives of her patients, many of whom have been using bioidentical hormones for years. She stressed the importance of educating more doctors about the benefits of HT, empowering women to take control of their own health, and encouraging them to move beyond fear-based reactions to a system that has historically provided misinformation.